BioXcel Therapeutics has filed for bankruptcy and lined up a deal for T | BioXcel Therapeutics has filed for bankruptcy and lined up a deal for Teva Pharmaceutical to acquire its assets for $57.5 million upfront.
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
BioXcel Chapter 11 sends BTAI shares sharply lower as Teva becomes the stalking horse bidder for IGALMI and BXCL501 assets.
Four months after Theravance Biopharma shut down its R&D unit, laid | Four months after Theravance Biopharma shut down its R&D…
With phase 3 results that have “exceeded” BioMarin’s expectations, according to R&D chief Greg Friberg, M.D., the California…
Faced with a dwindling bank account after a series of research setbacks, Biohaven is letting go of its most advanced experimental…
Teva is increasingly highlighting its innovative drug bona fides these days, seeking to style itself as both a novel…
Vertex Pharmaceuticals has struck a $10 billion deal—its largest ever—to acquire | Vertex Pharmaceuticals has struck a $10…
